摘要
目的探讨应用CEF方案(环磷酰胺+表柔比星+氟尿嘧啶)新辅助化疗对老年进展期乳腺癌患者的治疗效果。方法35例Ⅲ期老年乳腺癌患者行麦默通穿刺活检,均经病理检查确诊后,按CEF方案行新辅助化疗。化疗2～4个疗程不等。化疗后均行手术治疗。结果新辅助化疗后完全缓解5例,部分缓解26例,有效率88.6%,无临床进展病例。化疗的毒副作用主要表现为脱发、骨髓抑制和胃肠道反应。进展期乳腺癌降期的所有患者均接受手术治疗。随访中1例患者死于肺心病,2例死于肺转移,1例死于肝转移,2例发生骨转移。结论对身体状况较好的进展期老年乳腺癌患者新辅助化疗并不一定是化疗的禁区,部分患者仍能取得较好的疗效。
Objective To evaluate the therapeutic effect of combination of cyclophosphamide, epirubicin, and 5-fluorouracil （CEF） as neoadjuvant chemotherapy in the treatment of elderly patients with advanced breast cancer. Methods Thirty-five elderly patients with stage Ⅲ breast cancer aged 66 to 78 years were enrolled. All patients underwent Mammotome biopsy and pathological examination. Two to four courses of CEF as neoadjuvant chemotherapy were performed before operation. Results After CEF therapy, CR was in 5 cases, PR in 26 cases, and no patients had disease progression. The overall response rate was 88.6%. The side effect and toxicity were alopecie, myelosuppression and gastrointestinal reaction. Patients with down-staged breast cancer after chemotherapy all received operation. During the one to four year follow up survey, four patients died, one died from pneumocardial disease, two from lung metastasis and one from liver metastasis. Two patients had bone metastasis. Conclusions CEF demonstrated good disease control and toxicity profile in our patients. This approach provides an alternative for elderly patients. For advanced breast cancer patients with good physical status can use neoadjuvant chemotherapy. And a good therapeutic effect can be gained in some patients.
出处
《中华乳腺病杂志（电子版）》
CAS
2008年第6期18-21,共4页
Chinese Journal of Breast Disease(Electronic Edition)
关键词
新辅助化疗
老年人
进展期乳腺癌
Neoadjuvant chemotherapy
Patients, aged
Breast neoplasms, advanced
